[go: up one dir, main page]

PE20150672A1 - Formulaciones de opioides - Google Patents

Formulaciones de opioides

Info

Publication number
PE20150672A1
PE20150672A1 PE2015000092A PE2015000092A PE20150672A1 PE 20150672 A1 PE20150672 A1 PE 20150672A1 PE 2015000092 A PE2015000092 A PE 2015000092A PE 2015000092 A PE2015000092 A PE 2015000092A PE 20150672 A1 PE20150672 A1 PE 20150672A1
Authority
PE
Peru
Prior art keywords
buprenorphine
depot
opioid formulations
salts
opioid
Prior art date
Application number
PE2015000092A
Other languages
English (en)
Inventor
Fredrik Tiberg
Ian Harwigsson
Markus Johnsson
Original Assignee
Camurus Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53487482&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20150672(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US13/558,463 external-priority patent/US20130190341A1/en
Application filed by Camurus Ab filed Critical Camurus Ab
Publication of PE20150672A1 publication Critical patent/PE20150672A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dental Preparations (AREA)

Abstract

La invencion describe una formulacion precursora de deposito que comprende: a) una matriz de liberacion controlada; b) al menos solvente organico que contiene oxigeno; c) al menos 12 % en peso de al menos un agente activo que se selecciona de la buprenorfina y sales de esta, calculada como base libre de buprenorfina. Se proporcionan composiciones de deposito y metodos de tratamiento correspondientes en cuanto al manejo del dolor mediante mantenimiento con opioides y metodos relacionados
PE2015000092A 2012-07-26 2013-07-26 Formulaciones de opioides PE20150672A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/558,463 US20130190341A1 (en) 2004-06-04 2012-07-26 High bioavailability opioid formulations
US201361806185P 2013-03-28 2013-03-28

Publications (1)

Publication Number Publication Date
PE20150672A1 true PE20150672A1 (es) 2015-05-21

Family

ID=53487482

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015000092A PE20150672A1 (es) 2012-07-26 2013-07-26 Formulaciones de opioides

Country Status (20)

Country Link
US (3) US20240226091A9 (es)
JP (1) JP6417327B2 (es)
CN (1) CN109010255B (es)
AU (3) AU2016244271B2 (es)
CL (1) CL2015000197A1 (es)
CY (1) CY1124016T1 (es)
DK (1) DK2877155T3 (es)
EA (1) EA034855B1 (es)
ES (1) ES2837803T3 (es)
HK (1) HK1221636A1 (es)
HR (1) HRP20210068T1 (es)
HU (1) HUE053273T2 (es)
IL (3) IL296882A (es)
LT (1) LT2877155T (es)
MX (2) MX387722B (es)
MY (1) MY189481A (es)
NZ (2) NZ735248A (es)
PE (1) PE20150672A1 (es)
PT (1) PT2877155T (es)
SG (2) SG10201703964TA (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY189481A (en) 2012-07-26 2022-02-16 Camurus Ab Opioid formulations
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
CN111432807A (zh) * 2017-10-06 2020-07-17 铸造疗法股份有限公司 用于控制释放治疗剂的可植入贮库
WO2019136490A1 (en) 2018-01-08 2019-07-11 Foundry Therapeutics, Inc. Devices, systems, and methods for treating intraluminal cancer via controlled delivery of therapeutic agents
US12458589B2 (en) 2018-05-12 2025-11-04 Foundry Therapeutics, Inc. Implantable polymer depots for the controlled release of therapeutic agents
WO2020047013A1 (en) 2018-08-28 2020-03-05 Foundry Therapeutics, Inc. Polymer implants
WO2020240018A1 (en) * 2019-05-29 2020-12-03 Camurus Ab Administration device & regime
EP4294367A4 (en) * 2021-02-18 2025-02-12 Navin Saxena Research and Technology Private Limited Non-aqueous injectable composition for sustained release of buprenorphine and use thereof
TWI819756B (zh) * 2021-08-20 2023-10-21 大陸商蘇州恩華生物醫藥科技有限公司 包含塞納布啡的藥物組合物

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1136214A (en) 1965-06-15 1968-12-11 Reckitt & Sons Ltd Thebaine and oripavine derivatives
US3474101A (en) 1960-09-05 1969-10-21 Reckitt & Sons Ltd Thebaine and oripavine derivatives
GB8332556D0 (en) 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4610868A (en) 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
HU221308B1 (en) 1992-10-26 2002-09-28 Sanol Arznei Schwarz Gmbh Process for producing microcapsules
NZ276305A (en) 1993-11-16 1997-10-24 Depotech Corp Controlled release vesicle compositions
DE69510190T2 (de) 1994-03-30 2000-01-27 Gs Dev Ab Verwendung von fettsäureester als bioklebstoffe
KR100374098B1 (ko) 1994-04-08 2003-06-09 아트릭스 라보라토리스, 인코포레이션 조절된방출이식편형성에적합한액체전달조성물
SE518578C2 (sv) 1994-06-15 2002-10-29 Gs Dev Ab Lipidbaserad komposition
ATE223202T1 (de) 1994-09-30 2002-09-15 Mika Pharma Ges Fuer Die Entwi Pharmazeutische zusammensetzung
FR2726762B1 (fr) 1994-11-10 1997-01-17 Oreal Composition cosmetique ou dermatologique sous forme d'une dispersion d'une phase huileuse dans une phase aqueuse stabilisee a l'aide de particules de gel cubique et son procede d'obtention
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
JPH11513393A (ja) 1995-10-12 1999-11-16 ジーエス ディベロップメント エービー 皮膚又は粘膜表面へのもしくは介する活性物質の投与用医薬組成物
PT839525E (pt) 1996-10-31 2004-10-29 Takeda Chemical Industries Ltd Preparacao de libertacao prolongada
SE511313C2 (sv) 1997-01-13 1999-09-06 Gs Dev Ab Komposition med reglerad frisättning innefattande fettsyraester av diacylglycerol
BE1011899A6 (fr) 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
SE9802528D0 (sv) 1998-07-13 1998-07-13 Gs Dev Ab Bone tissue restoring composition
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
JP3952617B2 (ja) 1998-12-11 2007-08-01 株式会社日立製作所 内燃機関の排ガス浄化装置，排ガス浄化方法及び排ガス浄化触媒
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
JP4659943B2 (ja) 2000-02-25 2011-03-30 帝三製薬株式会社 塩酸ブプレノルフィン含有貼付剤
US6455066B1 (en) 2000-03-10 2002-09-24 Epicept Corporation Intradermal-penetration agents for topical local anesthetic administration
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6936187B2 (en) 2001-02-21 2005-08-30 Matthew Lawrence Lynch Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
US6656385B2 (en) 2001-02-21 2003-12-02 The Procter & Gamble Company Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
US20030003144A1 (en) 2001-05-01 2003-01-02 Keller Brian C. Sustained release formulations for nifedipine, dextromethorphan, and danazol
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20040022820A1 (en) 2001-11-28 2004-02-05 David Anderson Reversed liquid crystalline phases with non-paraffin hydrophobes
HUE039377T2 (hu) 2002-05-31 2018-12-28 L Molteni & C Dei Fratelli Alitti Soc Di Esercizio S P A Beültethetõ polimer eszköz buprenorfin folytonos kibocsátására
US7731947B2 (en) * 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20040259899A1 (en) 2003-04-08 2004-12-23 Sanghvi Suketu P. Combination therapy for constipation
US8865021B2 (en) 2003-11-07 2014-10-21 Camurus Ab Compositions of lipids and cationic peptides
WO2005110360A2 (en) 2004-05-18 2005-11-24 Phares Pharmaceutical Research N.V. Compositions for injection
GB0412530D0 (en) 2004-06-04 2004-07-07 Camurus Ab Formulation
NZ551990A (en) 2004-06-04 2011-01-28 Camurus Ab Liquid depot formulations
US9649382B2 (en) 2005-01-14 2017-05-16 Camurus Ab Topical bioadhesive formulations
ES2458992T3 (es) 2005-01-14 2014-05-07 Camurus Ab Formulaciones de análogos de GnRH
EP1845942B1 (en) * 2005-01-14 2014-04-09 Camurus Ab Gnrh analogue formulations
NZ560568A (en) 2005-01-21 2011-02-25 Camurus Ab Particulate compositions comprising phosphatidyl choline, diacyl glycerol or tocopherol, and a non-ionic stabilising amphiphile
US8546326B2 (en) 2005-06-06 2013-10-01 Camurus Ab Glp-1 analogue formulations
US10960077B2 (en) * 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US20070265329A1 (en) 2006-05-12 2007-11-15 Devang Shah T Methods for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)
CA2823407C (en) 2007-03-22 2016-10-18 Berg Pharma Llc Topical formulations having enhanced bioavailability
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
US8859579B2 (en) 2008-03-21 2014-10-14 Richard Andrew Sewell Compostions and methods for preventing and/or treating disorders associated with cephalic pain
GB0815435D0 (en) 2008-08-22 2008-10-01 Camurus Ab Formulations
US9226918B2 (en) 2008-12-04 2016-01-05 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating or preventing narcotic withdrawal symptoms
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
US8975270B2 (en) 2010-06-08 2015-03-10 Rb Pharmaceuticals Limited Injectable flowable composition comprising buprenorphine
GB2481018B (en) * 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
JP5938409B2 (ja) 2010-09-03 2016-06-22 ゾエティス・ベルジャム・エス・アー 高用量ブプレノルフィン組成物及び使用方法
CA2836847C (en) 2011-05-25 2021-06-29 Camurus Ab Controlled release peptide formulations
PE20141297A1 (es) 2011-12-05 2014-10-09 Camurus Ab Formulaciones peptidicas robustas de liberacion controlada
MY189481A (en) 2012-07-26 2022-02-16 Camurus Ab Opioid formulations
US9937164B2 (en) 2012-07-26 2018-04-10 Camurus Ab Opioid formulations
KR101586789B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 양이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
CN103142458B (zh) 2013-01-22 2015-09-09 莱普德制药有限公司 无成瘾性镇痛缓释递药系统的组方与制备方法
WO2014130887A1 (en) 2013-02-22 2014-08-28 Cedars-Sinai Medical Center Pancreatic insulin-producing beta-cell lines derived from human pluripotent stem cells
US9592227B2 (en) 2013-03-15 2017-03-14 Heron Therapeutics, Inc. Compositions of a polyorthoester and an aprotic solvent
US9393211B2 (en) 2013-03-15 2016-07-19 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
US20140323517A1 (en) 2013-04-30 2014-10-30 Heron Therapeutics, Inc. Compositions and methods for injection of a biodegradable polymer-based delivery system
JP6476658B2 (ja) 2013-09-11 2019-03-06 ソニー株式会社 画像処理装置および方法
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
GB201419091D0 (en) 2014-10-27 2014-12-10 Camurus Ab Formulations
US10471052B2 (en) 2015-02-19 2019-11-12 Mymd Pharmaceuticals, Inc. Method of treating addictions to opioids
GB201516554D0 (en) 2015-09-18 2015-11-04 Camurus Ab Controlled-release formulations
CN108348881A (zh) 2015-10-28 2018-07-31 托普索公司 乙苯脱氢成苯乙烯
IL319386A (en) 2018-10-11 2025-05-01 Indivior Uk Ltd Buprenorphine for the treatment of respiratory depression

Also Published As

Publication number Publication date
IL296882A (en) 2022-12-01
MX361873B (es) 2018-12-18
MY189481A (en) 2022-02-16
IL236762A0 (en) 2015-03-31
BR112015001548A2 (pt) 2017-07-04
MX387722B (es) 2025-03-18
AU2017279657A1 (en) 2018-01-18
NZ704012A (en) 2017-09-29
NZ735248A (en) 2018-10-26
HK1205948A1 (en) 2015-12-31
SG10201703964TA (en) 2017-06-29
ES2837803T3 (es) 2021-07-01
EA201590202A1 (ru) 2015-07-30
CL2015000197A1 (es) 2015-11-13
AU2017279657B2 (en) 2018-11-15
HK1221636A1 (en) 2017-06-09
CN109010255B (zh) 2022-10-21
AU2019200982A1 (en) 2019-02-28
AU2019200982B2 (en) 2019-07-18
JP2015522649A (ja) 2015-08-06
HRP20210068T1 (hr) 2021-03-05
PT2877155T (pt) 2020-12-18
US20250049783A1 (en) 2025-02-13
US20240131021A1 (en) 2024-04-25
HUE053273T2 (hu) 2021-06-28
LT2877155T (lt) 2021-02-25
US12161640B2 (en) 2024-12-10
CY1124016T1 (el) 2022-05-27
CN109010255A (zh) 2018-12-18
AU2016244271A1 (en) 2016-10-27
MX2015001033A (es) 2015-04-09
IL289157A (en) 2022-02-01
SG11201500554XA (en) 2015-02-27
US20240075024A1 (en) 2024-03-07
DK2877155T3 (da) 2021-01-18
JP6417327B2 (ja) 2018-11-07
US12318379B2 (en) 2025-06-03
EA034855B1 (ru) 2020-03-30
US20240226091A9 (en) 2024-07-11
AU2016244271B2 (en) 2018-01-18

Similar Documents

Publication Publication Date Title
CO7190238A2 (es) Formulaciones de opioides
PE20150672A1 (es) Formulaciones de opioides
DOP2017000261A (es) Derivados de ciclohexano sustituido con amido
PE20150668A1 (es) Formulaciones farmaceuticas topicas no acuosas
PE20151890A1 (es) Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
NZ746271A (en) Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
MX2018002326A (es) Analogos novedosos de nucleosidos sustituidos en el anillo aromatico biciclico 6-6 para su uso como inhibidores de prmt5.
ECSP13012499A (es) Nuevos compuestos
UY35040A (es) Pirrolopirimidinilamino-benzotiazolonas sustituidas
AR081774A1 (es) Composiciones farmaceuticas de co-cristales de tramadol y coxibs
CL2017001024A1 (es) Formulación de buprenorfina inyectable
UY33655A (es) Co-cristales y sales de inhibidores de ccr30
MX2018004304A (es) DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß.
DOP2016000007A (es) Pirazolpiridinas sustituidas
ES2531312T3 (es) Formulaciones, sales y polimorfos de transnorsertralina y usos de los mismos
DOP2013000004A (es) Agentes terapeuticos 976
NI201400066A (es) Anillo vaginal que comprende meloxicam y un agente modulador de la libración del principio activo, útil como anticonceptivo de uso continuo en mujeres
MX2019011610A (es) Derivados de quinoxalina y piridoprazina como inhibidores de pi3k-beta.
MX360017B (es) Formulación de aroma y fragancia (iv).
CL2015000310A1 (es) Uso de ipidacrina para el tratamiento de los trastornos de potencia, tal como trastornos de la actividad sexual; formulacion farmaceutica que contiene ipidacrina de 3 a 300 mg.
MX360531B (es) Formulación de aroma y fragancia (ii).
MX2015004315A (es) Formulacion de aroma y fragancia (vi).
CO7160072A2 (es) Síntesis de compuestos heterocíclicos
CO7131364A2 (es) Anillo vaginal que comprende meloxicam y un agente modulador de la liberación del principio activo, útil como anticonceptivo de uso continuo en mujeres
DOP2014000142A (es) Anillo vaginal que comprende meloxicam y un agente modulador de la liberación del principio activo, útil como anticonceptivo de uso continuo en mujeres

Legal Events

Date Code Title Description
FG Grant, registration